AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17057415
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg (subgroup of 6 volunteers)
Trial: 15111618
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HD-CT) with cyclophosphamide 1500 mg/m(2), thiotepa 150 mg/m(2), and mitoxantrone 10 mg/m(2) for 4 consecutive days followed by stem-cell support
Trial: 15111618
Drug: Standard-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose chemotherapy (SD-CT) with cyclophosphamide 500 mg/m(2), methotrexate 40 mg/m(2), and fluorouracil 600 mg/m(2) in three cycles
Trial: 15111618
Drug: Standard-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose chemotherapy (SD-CT)
Trial: 11692096
Drug: R-albuterol (6.25-1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-albuterol (6.25-1600 microg)
Trial: 11692096
Drug: RS-albuterol (12.5-3200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RS-albuterol (12.5-3200 microg)
Trial: 11692096
Drug: S-albuterol (6.25-1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-albuterol (6.25-1600 microg)
Trial: 9204651
Drug: Intravenous clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous clodronate (600 mg or 1500 mg in 500 mL of normal saline)
Trial: 9204651
Drug: Intravenous clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous clodronate
Trial: 9204651
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mL of saline)
Trial: 9204651
Drug: Blinded choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded choice of agent for pain improvement
Trial: 7966073
Drug: Weekly sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly sessions of supervised group physical therapy for a period of 9 months
Trial: 3475309
Drug: Group I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I: professional mechanical tooth‐cleaning, tongue‐scraping, chlorhexidine treatment, and oral hygiene instructions concentrated on the approximal surfaces, treatment given four times with intervals of two days, followed by one single treatment every six months
Trial: 3475309
Drug: Group II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II: same oral hygiene instructions as for Group I, repeated every six months
Trial: 3475309
Drug: Group III:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III: preventive program by local Dental Health Office, based on mechanical plaque control and topical use of fluorides and chlorhexidine
Trial: 25641556
Drug: Concizumab (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concizumab (subcutaneous or intravenous administration)
Trial: 16413229
Drug: Investigational treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational treatment
Trial: 14616411
Drug: voriconazole +
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: voriconazole + erythromycin (1 g twice daily on days 8-14)
Trial: 14616411
Drug: voriconazole +
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: voriconazole + azithromycin (500 mg once daily on days 12-14)
Trial: 11414066
Drug: Converting enzyme
RxNorm normalized name: Prohormone converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Converting enzyme inhibitor
Trial: 7955820
Drug: Simendan (doses:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simendan (doses: 2 mg, 5 mg, 10 mg)
Trial: 7955820
Drug: Simendan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simendan (5 mg and 10 mg doses)
Trial: 3024863
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg oral captopril after 1 week of diuretic therapy (50 mg/day furosemide)
Trial: 3024863
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day furosemide
Trial: 12716240
Drug: Lamotrigine (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (titrated from 25 mg/day to 100 mg/day for 6 weeks)
Trial: 11055559
Drug: Capsaicin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin (2 mg x kg(‐1) ingested 1 hour prior to heat exposure)
Trial: 8612382
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate tablet coingested with cimetidine (300 mg)
Trial: 8612382
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate solution coingested with cimetidine (300 mg)
Trial: 8612382
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate tablet coingested with famotidine (40 mg)
Trial: 24604360
Drug: Urea 10%
RxNorm normalized name: UREA 10% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea 10% applied to the oral cavity 3-4 times per day for 3 months
Trial: 12126242
Drug: Racecadotril (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racecadotril (100 mg, three times daily)
Trial: 12126242
Drug: Loperamide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (2 mg, three times daily)
Trial: 9886591
Drug: Duloxetine (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (exact dosage and duration not specified)
Trial: 9226525
Drug: Formula with
RxNorm normalized name: Stress B Formula with C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula with P:E ratio of 3.2 g/100 kcal
Trial: 9226525
Drug: Formula with
RxNorm normalized name: Stress B Formula with C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula with P:E ratio of 2.6 g/100 kcal
Trial: 27107668
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fluoxetine and interpersonal psychotherapy adapted to BPD (IPT-BPD)
Trial: 27107668
Drug: Single fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single fluoxetine administered for 32 weeks
Trial: 22516178
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative intestinal preparation (Control)
Trial: 17443678
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (enoxaparin 1 mg/kg per day) and antithrombin (AT) supplementation
Trial: 15660024
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of atorvastatin
Trial: 15660024
Drug: Higher starting
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Higher starting doses of atorvastatin
Trial: 8644481
Drug: proglumide 1600
RxNorm normalized name: proglumide
DrugBank: Proglumide (DB13431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: proglumide 1600 mg
Trial: 6987705
Drug: Protamine sulfate
RxNorm normalized name: Protamine Sulfate
DrugBank: Protamine (DB13700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Protamine sulfate administration post-procedural
Trial: 26781645
Drug: Inhalational Ciclesonide
RxNorm normalized name: ciclesonide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalational Ciclesonide (CIC) 640 mcg via metered-dose inhaler at admission and 24 hours later
Trial: 26781645
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no prophylactic therapy)
Trial: 26121349
Drug: Esomeprazole (2.5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (2.5-10 mg once daily for 2 weeks, then weight-adjusted doses for 4 weeks)
Trial: 23312760
Drug: Low lutein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low lutein (LL; 10 mg/d)
Trial: 23312760
Drug: High lutein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High lutein (HL; 20 mg/d)
Trial: 23312760
Drug: Lutein plus
RxNorm normalized name: Lutein Plus with Zeaxanthin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein plus zeaxanthin (LZ; each 10 mg/d)
Trial: 18829998
Drug: Verapamil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (1 mg)
Trial: 17711714
Drug: CYP1A1 MspI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP1A1 MspI polymorphism in smokers (CC genotype)
Trial: 17711714
Drug: CYP1A1 MspI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP1A1 MspI polymorphism in low dose cigarette smoking group (CC and TC genotypes)
Trial: 17711714
Drug: CYP1A1 MspI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP1A1 MspI polymorphism in high dose cigarette smoking group
Trial: 11473840
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 0.9% saline
Trial: 9517603
Drug: Conservative Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative Therapy (CT)
Trial: 525751
Drug: Pyritinol 600
RxNorm normalized name: pyritinol
DrugBank: Pyritinol (DB13084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyritinol 600 mg infused immediately after anaesthesia
Trial: 30925197
Drug: Daily breakfast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily breakfast (> 700 kcal by 11:00 am)
Trial: 24145042
Drug: Clostridial collagenase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clostridial collagenase ointment (CCO)
Trial: 19651562
Drug: Topical pimecrolimus
RxNorm normalized name: pimecrolimus Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical pimecrolimus 1% cream b.i.d. for 24 weeks
Trial: 19651562
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus 0.1% ointment b.i.d. for 24 weeks
Trial: 15111848
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) - 40 mg of enoxaparin
Trial: 15111848
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) - 5000 IU heparin
Trial: 8148303
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of 20 mL of an amide‐ester solution (1% lidocaine/0.2% tetracaine) with epinephrine 1:200,000
Trial: 8148303
Drug: Double injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double injection of two 10 mL injections of the same solution
Trial: 2900659
Drug: Steroids for
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids for at least 18 months
Trial: 2900659
Drug: Cytotoxic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic agents (27% of patients)
Trial: 31315670
Drug: bilateral erector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bilateral erector spinae block (20 mL 0.25% levobupivacaine)
Trial: 31315670
Drug: bilateral sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bilateral sham block (20 mL NaCl 0.9%)
Trial: 28322776
Drug: 250 mL/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL/h of normal saline
Trial: 28322776
Drug: 125 mL/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mL/h of 5% dextrose in normal saline
Trial: 28322776
Drug: 250 mL/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL/h of 2.5% dextrose in normal saline
Trial: 28322776
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (250 mL/h of normal saline)
Trial: 28322776
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (125 mL/h of 5% dextrose in normal saline)
Trial: 28322776
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (250 mL/h of 2.5% dextrose in normal saline)
Trial: 24174945
Drug: Septal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Septal injection of 40 U of BTA (Dysport(®), Ipsen Ltd)
Trial: 24174945
Drug: Turbinal injection
RxNorm normalized name: Karbinal
DrugBank: Carbinoxamine (DB00748)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Turbinal injection of 40 U of BTA (Dysport(®), Ipsen Ltd)
Trial: 21696934
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol (FSC) 250/50 μg twice-daily
Trial: 19929596
Drug: Intracameral bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intracameral bevacizumab injection at a concentration of 1.25 mg/0.05 mL
Trial: 19929596
Drug: Intracameral bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intracameral bevacizumab injection
Trial: 15116815
Drug: Fast-track rehabilitation
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-track rehabilitation with continuous epidural analgesia, enforced oral nutrition, mobilisation, planned early discharge
Trial: 8404935
Drug: Streptokinase initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase initiated 12-49 hours after onset of symptoms, followed by heparin for at least 5 days and warfarin and dipyridamole for at least 3 months
Trial: 8404935
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment without any of these drugs
Trial: 3950112
Drug: 1% indomethacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% indomethacin cream
Trial: 3950112
Drug: 1% meclofenamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% meclofenamate cream
Trial: 30374890
Drug: Remifentanil 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 12 ng/ml (Group 5)
Trial: 30374890
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (including Group 1: 0 ng/ml, Group 2: 2 ng/ml, Group 3: 4 ng/ml, Group 4: 8 ng/ml, Group 5: 12 ng/ml)
Trial: 26762908
Drug: Newer-generation drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer-generation drug-eluting stents (DES)
Trial: 26762908
Drug: Older-generation drug-eluting
RxNorm normalized name: black alder pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Older-generation drug-eluting stents (DES)
Trial: 26762908
Drug: Creatinine clearance
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatinine clearance (CrCl) <45 ml/min
Trial: 26762908
Drug: Creatinine clearance
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatinine clearance (CrCl) 45 to 59 ml/min
Trial: 26762908
Drug: Creatinine clearance
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatinine clearance (CrCl) ≥60 ml/min
Trial: 24332588
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy on the study side
Trial: 24332588
Drug: Sham ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ozone therapy on the control side
Trial: 20339731
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing + thought mapping + cognitive-behavioral group therapy
Trial: 15935383
Drug: Rifampin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (300 mg twice daily) and Azithromycin (500 mg every other day) for 6 months
Trial: 1895045
Drug: Early intravenous
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intravenous metoprolol followed by oral treatment for 15 days
Trial: 15219654
Drug: Antenatal betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antenatal betamethasone treatment (2 doses of 12 mg administered intramuscularly to the mother twelve hours apart)
Trial: 15219654
Drug: No antenatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antenatal betamethasone treatment
Trial: 12234700
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and VP-16 administered concurrently with radiotherapy (CRT)
Trial: 9664953
Drug: CsA (original
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA (original formulation of cyclosporine)
Trial: 2803892
Drug: Ephedrine 12.5
RxNorm normalized name: ePHEDrine 12.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 12.5 mg i.v. and 37.5 mg i.m.
Trial: 16584949
Drug: Hands-on therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hands-on therapy including heat, massage, and active exercises
Trial: 7952800
Drug: Propafenone administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone administered as a slow release formulation at 2 x 225 mg
Trial: 7952800
Drug: Propafenone administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone administered as a slow release formulation at 2 x 325 mg
Trial: 7952800
Drug: Propafenone administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone administered as a slow release formulation at 2 x 425 mg
Trial: 3306493
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g of elemental calcium per day
Trial: 25637395
Drug: Reference glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference glucose solution
Trial: 23734572
Drug: Rupatadine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine 20 mg daily for 4 weeks
Trial: 20142447
Drug: Bivalirudin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin plus glycoprotein IIb/IIIa inhibitors
Trial: 18982784
Drug: Continuous interscalene
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous interscalene block (CIB) - 7 mL/h infusion of bupivacaine 0.0625% plus 1 microg/mL of sufentanil
Trial: 18982784
Drug: Intra-articular analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular analgesia (IA) - 25 mL of ropivacaine 0.2% plus 2 mg of morphine
Trial: 1524746
Drug: Carbamide peroxide
RxNorm normalized name: Carbamide Peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamide peroxide bleaching gel applied for three 2-hour periods per day for 9 days
Trial: 1524746
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (5 teeth from each bonding agent group stored in water at 37 degrees C)
Trial: 3159546
Drug: Preparation A
RxNorm normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation A (Trigynon, triphasic OC with low doses of ethinylestradiol and levonorgestrel)
Trial: 3159546
Drug: Preparation B
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation B (Marvelon, monophasic OC with low doses of ethinylestradiol and desogestrel)
Trial: 3159546
Drug: Preparation C
RxNorm normalized name: other nasal preparation combinations in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation C (Ovidol, sequential OC with higher doses of ethinylestradiol and desogestrel)
Trial: 27314959
Drug: peginterferon beta-1a
RxNorm normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peginterferon beta-1a 125 mcg administered subcutaneously every 2 weeks
Trial: 27314959
Drug: peginterferon beta-1a
RxNorm normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peginterferon beta-1a 125 mcg administered subcutaneously every 4 weeks
Trial: 22855915
Drug: Cow's milk
RxNorm normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cow's milk (600 mL/d)
Trial: 22855915
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein isolate (SPI) beverage (840 mL/d; 30.1 mg total isoflavones/d)
Trial: 22855915
Drug: Whole soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole soy bean (WSB) beverage (840 mL/d; 91.4 mg total isoflavones/d)
Trial: 21086651
Drug: Emoxipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emoxipine (10 mg/kg, intravenous, 10-day course)